MBX
MBX Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About MBX
Mbx Biosciences, Inc.
A clinical-stage biopharmaceutical company focused on discovering and developing novel precision peptide therapeutics for the treatment of endocrine and metabolic diseases
11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032
--
MBX Biosciences, Inc., was incorporated in Indiana in August 2018 and transformed into a Delaware corporation in April 2019. They are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic diseases. Founded by global leaders, their companies take a transformative approach to the design and development of peptide medicines. Using this expertise, they designed their proprietary Precision Endocrine Peptide (PEPTM) platform to overcome the key limitations of unmodified and modified peptide therapy, improve clinical outcomes and simplify disease management for patients.
Company Financials
EPS
MBX has released its 2025 Q1 earnings. EPS was reported at -0.71, versus the expected -0.77, beating expectations. The chart below visualizes how MBX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
